All In Biotech

NDA 214621 · Sumitomo Pharma Am

Orgovyx

Relugolix · Oral · Gonadotropin Releasing Hormone Receptor Antagonist

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Dec 18, 2020

Approved uses

2

Original approval plus efficacy supplements

Registered trials

72

24 Phase 3, 27 recruiting

FAERS reports

24,260

6,066 serious, 1,187 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 8, 2026.

ORGOVYX is indicated for the treatment of adult patients with advanced prostate cancer. ORGOVYX is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of adult patients with advanced prostate cancer ( 1 ).

Mechanism: Relugolix is a nonpeptide GnRH receptor antagonist that competitively binds to pituitary GnRH receptors, thereby, reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and consequently testosterone.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 18, 2024 Supplement 6 · Efficacy LetterLabel
  • Dec 18, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
1 products under this application
  • ORGOVYX · RELUGOLIX 120MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Relugolix" as an intervention, any sponsor and status, largest first.

All 72 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hot flush7,658
  • fatigue5,907
  • therapy interrupted3,381
  • incorrect dose administered2,129
  • asthenia1,977
  • arthralgia1,592
  • diarrhoea1,554
  • dizziness1,344
  • product dose omission issue1,338
  • constipation1,049
  • death1,005
  • weight increased894

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20161
20171
20195
20203
2021472
20222,334
20232,979
20245,774
202510,315
20262,376

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Orgovyx (Relugolix)

2024 spending

$484M

Beneficiaries

28,521

180,761 claims

Per beneficiary

$16,981

$87.04 per unit

View as table
YearSpending
2020$0
2021$51,999,804
2022$165,989,470
2023$276,597,252
2024$484,308,516

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 48 on PubMed

Sponsor: Sumitomo Pharma Am

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.